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Background: PGC-1 and PGC-1 are 
metabolic coactivators that are dysregulated in 
muscle in many chronic diseases. 
Results: PGC-1 and PGC-1 differentially 
suppress expression of pro-inflammatory 
cytokines induced by various stimuli. 
Conclusion: In muscle cells, PGC-1 and PGC-
1 modulate the NF-B pathway thus 
profoundly affecting inflammatory processes.  
Significance: Targeting PGC-1 and PGC-1 in 
chronic diseases might reduce inflammation and 
thereby reverse disease progression. 
 
SUMMARY 
A persistent, low-grade inflammation 
accompanies many chronic diseases that are 
promoted by physical inactivity and improved 
by exercise. The beneficial effects of exercise 
are mediated in large part by PGC-1 while 
its loss correlates with propagation of local 
and systemic inflammatory markers. We 
examined the influence of PGC-1 and the 
related PGC-1 on inflammatory cytokines 
upon stimulation of muscle cells with TNF, 
toll-like receptor agonists and free fatty acids. 
PGC-1s differentially repressed expression of 
pro-inflammatory cytokines by targeting NF-
B signaling. Interestingly, PGC-1 and 
PGC-1 both reduced phoshorylation of the 
NF-B family member p65 and thereby its 
transcriptional activation potential. Taken 
together, the data presented here show that 
the PGC-1 coactivators are able to constrain 
inflammatory events in muscle cells and 
provide a molecular link between metabolic 
and immune pathways. The PGC-1s therefore 
represent attractive targets to not only 
improve metabolic health in diseases like type 
2 diabetes but also to limit the detrimental, 
low-grade inflammation in these patients. 
A sedentary lifestyle is a strong and 
independent risk factor for a large number of 
chronic diseases including musculoskeletal, 
metabolic, cardiovascular and neurological 
disorders. These diseases have been linked to a 
sterile, persistent, low-grade inflammation with 
elevated levels of circulating cytokines like 
interleukin 6 (IL-6), tumor necrosis factor  
(TNF) and IL-1 that often worsen disease 
progression (1-3). The nuclear factor B (NF-
B) pathway is a central regulator of 
inflammatory processes: NF-B activation has 
accordingly been associated with obesity and 
insulin resistance in different organs (4-6). A 
wide array of signals including cytokines like 
TNF and toll-like receptor (TLR) agonists of 
pathogenic or dietary origin (e.g. excess free 
fatty acids as in obesity (7)) is able to boost NF-
B activity upon cell surface receptor binding. 
These ligand-receptor interactions trigger the 
recruitment of adaptor proteins and receptor-
proximal kinases ultimately culminating in the 
activation of the inhibitor of NF-B (IB) kinase 
(IKK) complex. IKK subsequently 
phosphorylates IB which is then degraded by 
the proteasome. Decreased levels of IB free 
NF-B, thereby enabling cytosolic-nuclear 
translocation and ultimately transcriptional 
induction of a large amount of genes involved in 
immune function (8). The NF-B family 
comprises the 5 members RelA/p65, RelB, c-Rel, 
p100/p52 and p105/p50, of which the 
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heterodimer p65/p50 is the  most common form 
and the target of so-called “classical” NF-B 
activation (8). The transcriptional activity of p65 
is further modulated by post-translational 
modification i.e. inducible phosphorylation 
events that affect the binding affinity to 
coactivators and corepressors without altering 
the recruitment to DNA response elements 
(9,10). 
While physical inactivity clearly has a 
negative impact on health favoring an inflamed 
environment, regular, moderate exercise is 
beneficial against systemic inflammation and 
counteracts the development of chronic diseases 
(11). Besides prevention, exercise also is an 
effective therapeutic strategy to treat obesity, 
type 2 diabetes, sarcopenia and 
neurodegeneration (12-14). 
At the molecular level, many of the 
beneficial effects of exercise are mediated by the 
transcriptional coactivator peroxisome 
proliferator-activated receptor  coactivator 1 
(PGC-1) (15). PGC-1 is transiently induced 
by a single bout of exercise and chronically 
elevated in endurance trained muscle (16). 
Activated PGC-1 then controls the expression 
of genes encoding proteins involved in 
mitochondrial biogenesis, oxidative 
phosphorylation and other features of oxidative 
muscle fibers (17). Accordingly, mice with 
transgenic skeletal muscle-specific PGC-1 
overexpression perform better in endurance tests 
and display a switch towards oxidative type I and 
type IIA fibers (18,19). The increased fitness of 
healthy transgenic animals translates into 
improvement of symptoms when PGC-1 is 
expressed in the context of different muscle 
wasting conditions as shown for Duchenne 
muscular dystrophy, sarcopenia, a mitochondrial 
myopathy and denervation- or lovastatin-induced 
fiber atrophy (20-22). 
Inversely, a skeletal muscle-specific 
deletion of the PGC-1 gene facilitates a type 
IIB and type IIX fiber type switch, reduces 
exercise performance and promotes muscle fiber 
damage (23). Furthermore, loss of PGC-1 
results in elevated levels of pro-inflammatory 
factors locally in muscle as well as systemically 
(24). These findings suggest an anti-
inflammatory role for PGC-1: in fact, in 
skeletal muscle of diabetic patients, PGC-1 
levels negatively correlate with IL-6 or TNF 
levels independent of BMI (24). 
PGC-1, a close related member of the 
PGC-1 gene family, also exhibits dysregulated 
expression in skeletal muscle of diabetic patients 
and thereby contributes to the mitochondrial 
dysfunction observed in type 2 diabetes (25). 
While both PGC-1s share the ability to boost 
oxidative metabolism, PGC-1 is not regulated 
by exercise and primarily drives the formation of 
type IIX fibers (26). Interestingly, PGC-1 is 
required for alternative activation of and 
mitochondrial ROS production in macrophages 
(27,28); an immunomodulatory role in skeletal 
muscle has however not been described so far. 
Based on these observations, we now 
tested the hypothesis that the PGC-1 coactivators 
exert anti-inflammatory effects in muscle. More 
precisely, we explored if PGC-1 and PGC-1 
are able to modify cytokine expression upon 
exposure of muscle cells to different 
inflammatory stimuli like TNF, TLR agonists 
and free fatty acids (FFAs). We found that the 
PGC-1s repress the transcriptional activity of 
p65 and thereby modulate the NF-B signaling 
pathway. These data represent a prime example 
of crosstalk between metabolic and immune 
pathways with important implications for 
skeletal muscle function. 
 
EXPERIMENTAL PROCEDURES 
Cell culture and treatments: The mouse 
skeletal muscle cell line C2C12 was maintained 
below confluence in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% fetal 
calf serum and 1x Penicillin/Streptomycin 
(Invitrogen). For differentiation into myotubes, 
growth medium was exchanged for DMEM 
supplemented with 2% horse serum (Invitrogen) 
for at least 3 days. PGC-1, PGC-1 and GFP 
were overexpressed from recombinant 
adenoviral constructs 48 h prior to treatment. 
Stimulation with TNF (Sigma-Aldrich) and 
TLR agonists (Invivogen) in growth or 
differentiation medium lasted for 2 h unless 
otherwise stated. Concentrations were as 
follows: TNF 10ng/ml, PAM3CSK4 1g/ml 
(TLR1/2 agonist), HKLM 10
8
 cells/ml (TLR2 
agonist), poly(I:C) 25g/ml (TLR3 agonist), 
E.coli K12 LPS 1g/ml (TLR4 agonist), S. 
typhimurium flagellin 1g/ml (TLR5 agonist), 
FSL1 1g/ml (TLR6/2 agonist), ssRNA40 
1g/ml (TLR8 agonist) and ODN18266 5M 
(TLR9 agonist). Free fatty acids (FFA, Sigma-
Aldrich) were dissolved in ethanol and further 
diluted to 1mM final concentration in DMEM 
containing 2% fatty acid- and endotoxin-free 
bovine serum albumin (Sigma-Aldrich); FFA 
treatment lasted for 16 h in serum-free medium. 
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The protein phosphatase inhibitor okadaic acid 
(OA, Sigma-Aldrich, 250nM) was present 30 
minutes prior to and during treatment with TNF 
where indicated, while control samples were 
incubated with vehicle (DMSO, 0.04%) alone for 
equal times. The PPAR inhibitor MK 886 
(Tocris Bioscience, 20µM) was present 24 h 
prior to and during treatment with TNF where 
indicated, while control samples were incubated 
with vehicle (DMSO, 0.02%) alone for equal 
times. 
Semiquantitative real-time PCR: RNA 
was isolated from treated C2C12 cells using 
Trizol (Invitrogen) and residual DNA 
contamination was removed by DNase I 
digestion (Invitrogen). 1g of RNA was reverse 
transcribed with SuperScript II (Invitrogen) and 
the resulting cDNA used as template for RT-
PCR. To detect relative expression levels, cDNA 
was amplified with the SYBR Green Master mix 
(Applied Biosystems) and analyzed on a 
StepOnePlus RT-PCR System (Applied 
Biosystems). The respective primer pairs are 
listed in Supplemental Table 1. All values are 
normalized to the expression of TATA-Box 
binding protein (TBP) and expressed as fold 
induction over the untreated control condition.  
ELISA: To determine cytokine 
concentrations in cell culture supernatants, 
sandwich immunoassays against IL-6 were 
performed according to the manufacturer’s 
instructions (Quantikine, R&D Systems).  
NF-B Customized Array analysis: 
Differentiated C2C12 cells overexpressing PGC-
1, PGC-1 or GFP were treated with TNF for 
2h and RNA was extracted (NucleoSpin RNA II, 
Macherey-Nagel). The custom array analysis 
was subsequently performed as previously 
described (29). Briefly, RNA was processed with 
the Amino Allyl MessageAMP II aRNA 
Amplification Kit (Ambion) according to the 
manufacturer’s instructions to yield aminoallyl-
modified aRNA that was further coupled to Cy3 
or Cy5 dyes respectively. Biological duplicates 
were labeled crosswise to control for dye effects. 
Pairs of samples were hybridized on a total of 14 
slides containing probes for 524 genes included 
in the array as described elsewhere (29, 
ArrayExpress A-MEXP-1502). Significantly 
regulated genes as determined by ANOVA 
(P≤0.01) were subject to cluster analysis. The 3 
resulting clusters were the source of further 
KEGG (Kyoto Encyclopedia of Genes and 
Genomes) and GO (Gene Ontology) terms 
enrichment analysis with FatiGO (30) 
considering the adjusted p-value≤0.05 as 
significant. To predict the relevant transcription 
factors for the regulation of each cluster, motif 
search within a region spanning +200bp to -
800bp around the transcription start site (TSS) of 
each gene in the array was performed using 
MotEvo (31) in combination with a non-
redundant set of position weight matrices mainly 
derived from JASPAR and TRANSFAC. 
Overrepresented motifs were retrieved by 
comparing binding site occurrence in each 
cluster to the occurrence in the whole array and 
considered significant with a z score ≥2. 
Microarray data were further analyzed with 
MARA (Motif Activity Response Analysis (32)) 
to predict the most important transcription 
factors that contribute to the changes in gene 
expression in our set of samples (independent of 
clustering).  
Dual-luciferase reporter gene assays: 90 
– 95% confluent C2C12 myoblasts were 
transfected using Lipofectamin 2000 (Invitrogen) 
with plasmids containing firefly luciferase under 
the control of 3 NF-B sites (wildtype, wt) or a 
construct with mutated sites as control in 
combination with renilla luciferase as internal 
control. Cells were then either treated with 
TNF/ TLR agonists for 2h, or co-transfected 
with p65, increasing amounts of PGC-1/ and 
empty vector (pcDNA3.1) to keep total DNA 
concentration constant. Cells were assayed 24h 
post transfection with the Dual-Luciferase 
Reporter Assay System (Promega) according to 
the manufacturer’s protocol. Briefly, cells were 
lysed and firefly and renilla luciferase activities 
determined on a Centro LB 960 luminometer 
(Berthold Technologies). Firefly-derived 
luciferase values were normalized to renilla 
activity and results expressed as ratio of wt to 
mutated reporter with the control condition being 
arbitrarily set to 1. 
TransAM NF-B DNA binding assays: 
Nuclear extracts from myotubes were prepared 
by swelling of the cells in hypotonic buffer 
(20mM Hepes, pH 7.5, 5mM NaF, 10M 
Na2MoO4, 0.1mM EDTA) and breaking the 
cytoplasmic membrane with Nonidet P-40 
substitute (0.5%). After centrifugation, the 
residual nuclear pellet was resuspended in 
Complete Lysis Buffer to dismantle nuclear 
membrane integrity and obtain the nuclear 
extract as supernatant of the final, fast 
centrifugation step. To determine the amount of 
active NF-B in these nuclear extracts, TransAM 
assays (Active Motif) were performed following 
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the manufacturer’s instructions. In brief, 10 g 
of nuclear extracts were added to wells coated 
with oligonucleotides containing the NF-B 
consensus sequence (5’-GGGACTTTCC-3’). 
These oligonucleotides trap active transcription 
factors, which then are detected in an ELISA-
like assay with specific primary antibodies for 
the different NF-B subunits and a secondary 
horseradish peroxidase (HRP)-conjugated 
antibody. A colorimetric reaction accordingly 
determines the amount of NFB-DNA binding. 
Results are expressed in arbitrary units minus the 
respective blank value, and normalized to Ctrl 
conditions.  
Western Blotting: After washing away 
residual culture medium with PBS, cells were 
scraped off the dish in lysis buffer (20mM Tris-
HCl pH7.5, 150mM NaCl, 1mM EDTA, 1mM 
EGTA, 1% Triton X-100, 2.5mM Na4P2O7,1mM 
-glycerophosphate, 1mM Na3VO4) 
supplemented with protease- (complete tablets, 
Roche) and phosphatase inhibitors (phosphatase 
inhibitor cocktail 2, Sigma-Aldrich) and kept on 
ice for 10 min with occasional vortexing. 
Centrifugation at 10’000g yielded the protein 
lysate, which was subjected to SDS-PAGE. The 
resolved proteins were transferred to a 
nitrocellulose membrane (Whatman) on a semi-
dry electroblotting system (Thermo Scientific) 
with 1.5mA/cm
2
 and transfer confirmed by 
Ponceau S staining (0.1% in 5% acetic acid). 
Proteins were detected with the following 
primary antibodies: anti-p65, anti-Pp65(ser536) 
(both Cell Signaling Technology), anti-p105/p50 
(abcam), anti-p100/p52, anti-RelB, anti-cRel, 
anti-IB, anti-IBanti-IKK, anti-IKK, 
anti--tubulin as loading control (all Cell 
Signaling Technology) and an anti-rabbit-IgG 
HRP-coupled secondary antibody (Dako). Bands 
were finally visualized by autoradiography with 
ECL substrate (Pierce) and density quantified 
with ImageJ software.  
Statistical analysis: Data were analyzed 
with student’s t test using P≤0.05 as the 
significance threshold. 
 
RESULTS 
PGC-1 and PGC- differentially 
suppress pro-inflammatory cytokine expression. 
and secretion To delineate the effect of PGC-1s 
on inflammatory processes in muscle, myotubes 
overexpressing either adenovirally encoded 
PGC-1 or PGC-1 were compared to GFP-
expressing control cells treated with different 
inflammatory stimuli. PGC-1 coactivator 
overexpression was high and functional as 
evident from the induction of the known target 
gene medium-chain acyl-coenzyme A 
dehydrogenase (MCAD, Suppl. Fig. 1A and 1B). 
Ectopic, recombinant TNF strongly induced the 
gene expression of the pro-inflammatory markers 
IL-6, TNF and macrophage inflammatory 
protein-1 (MIP-1/CCL3). While PGC-1 did 
not negatively affect basal levels of these pro-
inflammatory cytokines, it diminished their 
induction by TNF yielding lower levels than in 
control cells (Fig. 1A). PGC-1 suppressed both 
basal and TNF-induced expression of IL-6, 
TNF and MIP-1 (Fig. 1B). As a consequence 
of the PGC-1-mediated repression in gene 
expression, lower levels of secreted IL-6 protein 
were observed in culture media after TNF 
treatment (Fig. 1C and 1D). 
Next, we examined the effect of PGC-1s 
on TLR stimulation in muscle cells. First, we 
assessed the expression pattern of the TLRs in 
our experimental system and found that TLR1, 
TLR2, TLR3, TLR 4, TLR6, and at lower levels 
TLR5 were detectable in the muscle cells (Fig. 
2A). To study the activity of the TLRs, selective 
agonists for TLR2, TLR3, TLR4, TLR5, TLR8, 
TLR9, or the TLR1/2 and TLR6/2 heterodimers 
were applied. Of those, only TLR1/2, TLR4 and 
TLR6/2 activators consistently elevated 
expression of IL-6 and TNF (Fig. 2B). 
Moreover, the same compounds increased 
luciferase reporter gene activity controlled by 3 
repeats of a minimal NF-B DNA-response 
element (Fig. 2C). For the subsequent 
experiments, agonists for TLR1/2, TLR4 and 
TLR6/2, the active TLRs in muscle cells, were 
utilized and compared to the TLR3 activator that 
was used as a negative, internal control. TLR1/2, 
TLR4 and TLR6/2 agonists all induced 
expression of IL-6 and TNF in control cells as 
expected (Fig. 2D). Interestingly, PGC-1 
effectively repressed TLR-mediated TNF 
expression by all of the active agonists while IL-
6 expression was only reduced by PGC-1 in the 
TLR1/2 and TLR4 agonist treatment (Fig. 2D). 
PGC-1 furthermore lowered basal IL-6 protein 
secretion, but not the elevated IL-6 secretion 
caused by TLR agonist stimulation (Fig. 2E). In 
contrast, PGC-1 significantly decreased IL-6 
and TNF gene expression both in the basal state 
and after activation of TLR1/2 while no effect 
was observed in the TLR4 or TLR6/2 agonist 
treated cells (Fig. 2F). Nevertheless however, IL-
6 secretion into culture medium was strongly 
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repressed by PGC-1 in all of the different 
experimental conditions (Fig. 2G). 
As a third inflammatory stimulus besides 
TNF and TLR agonists, the free fatty acids 
(FFA) palmitic acid (C16H32O2), oleic acid 
(C18H34O2), myristic acid (C14H28O2), stearic acid 
(C18H36O2), linoleic acid (C18H32O2) and elaidic 
acid (C18H34O2) were administered to muscle 
cells to mimick the lipid overload that is 
associated with disease progression in the 
metabolic syndrome. As expected, saturated fatty 
acids, in particular stearic and palmitic acid and 
to a lesser extent the shorter-chain species, 
produced a strong pro-inflammatory response as 
indicated by the transcriptional induction of the 
IL-6, TNF and MIP-1 genes (Fig. 3A). In 
contrast, mono- or polyunsaturated fatty acids 
did not alter pro-inflammatory cytokine 
expression (Fig. 3A); in fact, oleic acid was even 
able to reverse the negative effects of palmitic 
acid (Fig. 3A) as previously described (33). 
Strikingly, PGC-1 potently inhibited the 
increase in IL-6, TNF and MIP-1 gene 
expression mediated by palmitic, myristic and 
stearic acid (Fig 3A). Likewise, PGC-1 also 
efficiently blocked the FFA-induced elevation of 
IL-6 and MIP-1 transcript levels (Fig. 3B). 
Interestingly however, transcriptional elevation 
of TNF by palmitic, myristic and stearic acid 
was unaffected by overexpression of PGC-1 
(Fig 3B).  
PGC-1 and PGC-1 target the NF-B 
pathway to suppress inflammation. To examine 
the mechanisms behind the repressive effect of 
the PGC-1 coactivators on TNF-induced pro-
inflammatory cytokines, a customized array 
designed to represent the most important 
inflammatory genes and other NF-B targets 
(29) was employed. Out of the 524 genes that are 
present on the array, 55 genes were found to be 
differentially regulated by TNF treatment 
and/or PGC-1 overexpression (P <0.01) and thus 
further analyzed. These 55 genes were grouped 
into 3 clusters (Fig. 4A): cluster 1 contained 21 
genes that were upregulated by PGC-1 and 
PGC-1 including vascular endothelial growth 
factor (VEGF), a known PGC-1 target (34). 
The 13 and 21 genes in clusters 2 and 3, 
respectively, were repressed by PGC-1 and 
PGC-1. Importantly, genes in cluster 3 were 
TNF-inducible while the expression of the 
genes in cluster 2 was not modulated by TNF 
treatment (Fig. 4A). To validate the results of the 
microarray, three representative genes from each 
cluster were chosen and their expression 
analyzed by real-time PCR. Mitochondrial 
translational initiation factor 2 (Mtif2), VEGF 
and protein arginine methyltransferase 1 (Prmt1) 
from cluster 1 were indeed induced (Suppl. Fig. 
2A) while chemokine (C-X-C motif) ligand 12 
(Cxcl12), complement component 2 (C2) and 
E2F transcription factor 2 (E2f2) from cluster 2 
(Suppl. Fig 2B) and chemokine (C-C motif) 
ligand 2 (Ccl2), Ccl7 and Cxcl1 from cluster 3 
(Suppl. Fig. 2C) were repressed by PGC-1 
coactivators confirming the results of the 
microarray. Furthermore, TNF-inducibility of 
genes in cluster 3 was verified.  
Functionally, the genes in cluster 1 were 
enriched in only one Gene Ontology (GO) term 
compared to 18 significant terms in cluster 2 and 
96 terms in cluster 3 (of which only 46 terms 
with a p-value≤0.01 are shown) (Suppl. Fig. 
3). 12 of the GO categories in cluster 2 and 26 
categories in cluster 3 are related to 
inflammation and immunity. Importantly, the 
inflammation-related GO terms comprise the top 
10 and top 15 ranking categories in clusters 2 
and 3, respectively (Suppl. Fig. 3). Likewise, all 
3 KEGG pathways assigned to cluster 2 and the 
top 9 KEGG pathways out of 11 of cluster 3 are 
related to inflammatory signaling (Fig. 4B). 
These results suggest that the PGC-1s are able to 
repress inflammatory processes in muscle cells. 
To predict which transcription factors 
are involved in the regulation of each cluster, 
promoter regions were analyzed in regard to their 
motif composition. Motifs overrepresented in 
each of the clusters are listed in Suppl. Table 2A. 
As background for this analysis, all promoters of 
the microarray were used, thereby eliminating 
any putative bias that might have been 
introduced with the specific choice of genes in 
the customized microarray. The majority of 
predicted binding sites were unique to one 
cluster, i.e. 26 out of 33 motifs in cluster 1, 20 
out of 26 motifs in cluster 2 and 21 out of 28 
motifs in cluster 3 (Suppl. Table 2B). 
Intriguingly, one distinct transcription factor 
binding motif stood out as the clear top ranking 
candidate in each of the three clusters based on z 
score, namely NFY{A,B,C} in cluster 1 (z score 
of 9.74 compared to the second ranking z score 
of 4.9 for GFI1), IRF1,2,7 in cluster 2 (z score of 
6.98 compared to 4.46 for FOX{F1,F2,J1}) and 
NFB1_REL_RELA in cluster 3 (z score of 6.67 
compared to 4.93 for AR) (Fig. 4C and Suppl. 
Table 2A). These predictions indicate that the 
NF-B pathway is a likely target for the PGC-1s 
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to suppress TNF-inducible inflammatory gene 
expression represented in cluster 3. Accordingly, 
NF-B was also the highest scoring motif in the 
Motif Activity Response Analysis (MARA) of 
the whole array and thus the most likely 
transcription factor to modulate TNF- and 
PGC-1-dependent gene expression (Fig. 4D).  
PGC-1 reduces p65 and p50 expression 
levels. To experimentally validate the 
biocomputational prediction of PGC-1-mediated 
repression of NF-B signaling as the central 
mechanism for the anti-inflammatory effect of 
the PGC-1 coactivators on TNF-inducible 
genes, reporter gene assays were performed with 
a construct containing the luciferase gene under 
the control of 3 NF-B DNA response elements. 
The activity of the reporter gene construct in 
response to TNF treatment resembles 
endogenous IL-6 and TNF gene expression 
(Suppl. Fig. 1C and 1D). Increasing amounts of 
co-transfected PGC-1 or PGC-1 progressively 
inhibited transcription from a NFB-responsive 
promoter that is activated by exogenous p65 
(Fig. 5A). 
To elucidate the mechanism by which 
the PGC-1 coactivators repress NF-B activity 
even on minimal NF-B response element-
driven gene expression, we first examined the 
expression levels of the different NF-B family 
members before and after TNF treatment and 
PGC-1 overexpression, respectively (Fig. 5B and 
5C). TNF led to a significant increase in 
transcript levels of all 5 NF-B isoforms (p65, 
p105/p50, p100/p52, RelB and c-Rel) in GFP-
infected control cells. PGC-1 did not change 
the levels of the canonical isoforms p65 and 
p105/p50 as well as RelB in the basal, vehicle-
treated cells while an induction of p100/p52 was 
observed suggesting a switch towards the 
noncanonical NF-B pathway. In contrast to the 
first 4 NF-B isoforms, c-Rel expression was 
clearly reduced by PGC-1 overexpression (Fig. 
5B). After TNF treatment, the levels of all NF-
B isoforms tended to be lower in PGC-1 
overexpressing cells, however only reaching 
statistical significance in the case of c-Rel gene 
expression (Fig 5B). In striking contrast to the 
PGC-1-mediated effect, PGC-1 suppressed 
p65 and p105/p50 as well as RelB and c-Rel 
gene expression in the basal state (Fig. 5C). The 
transcript levels of all 5 NF-B isoforms tended 
to be lower in PGC-1 overexpressing cells after 
TNF treatment; similar to PGC-1 
overexpressing cells, this repression was 
however only significant for c-Rel gene 
expression (Fig. 5C). Therefore, while the basal 
repression of p65 and p105/p50 could contribute 
to the strong repression of inflammatory gene 
expression by PGC-1 in non-stimulated cells, it 
is unlikely that the small differences in 
expression levels of the different NF-B 
isoforms after TNF treatment underlie the 
profound effects of PGC-1s on pro-inflammatory 
cytokine expression in stimulated muscle cells. 
Thus, to further elucidate the molecular 
mechanism underlying this observation, we next 
assessed the DNA binding capability of all NF-
B family members in the context of TNF 
treatment and PGC-1 overexpression (Fig. 5D 
and 5E). Of the 5 NF-B isoforms, RelB and c-
Rel were undetectable in nuclear extracts from 
C2C12 myotubes in the TransAM assay and are 
thus unlikely to play a major role in the 
regulation of pro-inflammatory cytokine 
expression in our experimental context of muscle 
cells as hypothesized in other publications (35). 
The DNA binding of p50 and p52 was detectable 
though low (Fig. 5D and 5E). In contrast, 
recruitment of p65 to DNA response elements 
was substantial in non-stimulated cells and 
further elevated after TNF treatment. 
Interestingly however, DNA binding of p65 with 
and without TNF treatment, respectively, was 
not changed by PGC-1 (Fig. 5D) while PGC-1 
strongly inhibited binding of p65 and p50 to 
DNA in the basal, vehicle-treated muscle cells 
(Fig. 5E). Comparable to PGC-1 
overexpression, DNA binding of any of the NF-
B isoforms was not affected by ectopic PGC-1 
in TNF-stimulated cells (Fig. 5E). It is thus 
conceivable that both low p65/p50 expression as 
well as reduced DNA binding account for the 
PGC-1-mediated reduction in pro-inflammatory 
cytokine expression compared to vehicle-treated 
control cells. In contrast however, the diminished 
levels of these cytokines upon TNF treatment 
in both PGC-1- and PGC-1-overexpressing 
cells can neither be attributed to changes in NF-
B expression nor to modulation of the NF-B 
protein binding capability to DNA response 
elements.  
PGC-1 and PGC-1 diminish the 
transcriptional activity of p65. Based on our data 
implying alternative molecular mechanisms 
distinct from transcriptional regulation or DNA 
binding of NF-B to underlie the repressive 
action of the PGC-1 coactivators on the activity 
of this transcription factor, we next studied 
upstream signaling and the post-translational 
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modification of p65 that influence the 
transcriptional activity of NF-B. First, we 
examined the possibility that high levels of IBs 
after TNF treatment could account for lowered 
cytokine expression. However, the relative 
amount of IB protein was not different 
between conditions (Fig. 6A). IB, an NF-B 
target gene, was accordingly increased on the 
protein level by TNF treatment and reduced in 
muscle cells overexpressing PGC-1 or PGC-1 
(Fig. 6A and Suppl. Fig. 4A and 4B), similar to 
other NF-B targets such as IL-6 and TNF 
(Fig. 1) excluding the possibility of IB-
mediated repression. Subsequently, IKK protein 
levels were assessed: IKK was not and IKK 
was barely detectable (Fig. 6A). In contrast, 
IKK was slightly increased by TNF 
treatment; this effect was abrogated in cells 
overexpressing PGC-1 or PGC-1 (Fig. 6A). 
IKK is one of the protein kinases that is able to 
phosphorylate p65 at serine 536. Importantly, the 
phosphorylation status of p65 at serine 536 
affects the transcriptional activity of NF-B even 
when bound to DNA response elements (10). In 
Western blot analyses of total and 
phosphorylated p65 protein, a small but 
significant increase in total p65 protein levels 
was observed after TNF treatment in control 
cells (Fig 6A and 6B). PGC-1 overexpression 
did not affect basal levels of p65, while PGC-1 
diminished total p65 protein expression in this 
context, as expected based on the reduced 
mRNA expression of p65 in PGC-1 
overexpressing muscle cells (Fig. 5C). Strikingly 
however, both PGC-1 and PGC-1 reduced 
TNF-mediated phosphorylation of p65 by 
about 50% (Fig. 6A and 6B). None of the other 
NF-B family members underwent regulation by 
TNF on the protein level. Interestingly, PGC-
1 overexpression resulted in elevated protein 
levels of p105, p100, p52 and RelB in non-
stimulated muscle cells and, to a smaller extent, 
of p105 and p100 in TNF-treated cells again 
suggesting a PGC-1-dependent increase in the 
non-canonical NF-B pathway (Fig. 6A and 
Suppl. Fig. 4A). In contrast, PGC-1 does not 
seem to elevate the non-canonical NF-B family 
members like PGC-1. Thus, besides the strong 
increase in c-Rel protein and the more moderate 
elevation of p105 protein in non-stimulated cells, 
PGC-1 significantly reduced RelB protein 
levels (Fig. 6A and Suppl. Fig. 4B). The 
discrepancy between the PGC-1-mediated 
repression of c-Rel gene expression compared to 
the elevation of c-Rel protein levels implies post-
transcriptional effects in the regulation of this 
particular NF-B family member. 
Dephosphorylation and transrepression 
of p65 are potential molecular mechanisms for 
diminished cytokine expression. To further 
substantiate the findings implying that the PGC-
1 coactivators modulate NF-B activity by 
preventing p65 phosphorylation, we examined 
other upstream effectors for this phosphorylation 
as well as downstream events affecting the 
DNA-bound NF-B transcriptional complex. 
The protein kinase Akt has been implicated in 
the regulation of the NF-B signaling pathway 
upstream of IKK (36) one of the protein 
kinases to mediate p65 phosphorylation and of 
which protein levels are reduced by PGC-1 and 
PGC-1 overexpression (Fig. 6A). As expected, 
based on these findings, PGC-1 and PGC-1 
diminished Akt activation as evident from 
diminished phospho-Akt (ser473) levels 
normalized to total Akt protein (Fig. 7A). 
To obtain a more accurate picture of p65 
phosphorylation, a time course experiment was 
performed. It revealed that p65 is phosphorylated 
at serine 536 after 5 minutes of TNF treatment 
even in the presence of PGC-1 and PGC-1 
(Fig. 7B and 7C) implying the possibility that not 
only an altered kinase profile but also activity of 
a protein phosphatase might be involved in the 
PGC-1-mediated modulation of NF-B 
phosphorylation. We therefore tested whether 
pharmacological inhibition of protein 
phosphatase 2A (PP2A) and PP1, two enzymes 
that dephosphorylate p65 (37), by okadaic acid 
abolishes the repression of p65 phosphorylation 
mediated by PGC-1 and PGC-1 in muscle 
cells. As expected, okadaic acid powerfully 
stabilized phosphorylation of p65 at serine 536 
(Fig. 7D and 7F). Strikingly however, PGC-1 
and PGC-1 overexpression (Fig. 7D and 7E) 
still reduced p65 phosphorylation, even in 
okadaic acid-treated cells (Fig. 7D and 7F). 
Thus, while PP1 and PP2A clearly affect the 
serine 536 phosphorylation of p65 in our 
experimental context, these two phosphatases are 
most likely not involved in the modulation of 
p65 phosphorylation by the PGC-1s.  
Since the phosphorylation status of p65 
affects its affinity to cofactors (38), we also 
determined the expression levels of the 
coactivator CBP and corepressors NCoR and 
SMRT. Of those, only SMRT transcript levels 
were significantly increased by PGC-1 (Fig 8A 
and 8B). A well-described mechanism of 
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inhibition of inflammatory gene expression is 
mediated by nuclear receptors and termed 
transrepression (39). We evaluated the gene 
expression of potential candidates for 
transrepression and found PPAR to be strongly 
induced by both PGC-1 and PGC-1 in non-
stimulated and TNF-treated muscle cells 
similar to previous data (40) (Fig 8A and 8B). 
PPAR therefore likely contributes to the PGC-
1-dependent reduction in NF-B transcriptional 
activity by impairing the exchange of 
corepressors for coactivators that is necessary to 
effectively initiate transcription. In fact, 
inhibition of PPAR recovered expression of IL-
6 and TNF in the presence PGC-1 (Suppl. Fig 
5). 
 
DISCUSSION 
With an aging population and an 
increasingly sedentary lifestyle, chronic diseases 
are on the rise. Obesity and its comorbidities but 
also some cancers and neurodegeneration have 
been associated with local and systemic 
inflammation that worsens disease progression, 
while exercise has beneficial effects in many of 
these disorders and even acts preventive (41). 
PGC-1 is a major molecular mediator of 
exercise in skeletal muscle and its loss not only 
disturbs metabolic processes but also evokes a 
local and systemic inflammation (24). In the 
present report we thus tested the idea that PGC-1 
coactivators have anti-inflammatory properties.  
Indeed, we confirmed such properties as 
PGC-1 and PGC-1 were able to diminish the 
increase in pro-inflammatory cytokines elicited 
by different inflammatory stimuli such as TNF, 
TLR agonists and saturated FFAs. We identified 
the NF-B pathway as main target of PGC-1-
dependent repression. These results are 
complemented by in vivo findings of Brault and 
coworkers who showed that NF-B reporter 
activity decreases after electroporation of tibialis 
anterior muscle with PGC-1 / PGC-1 in the 
context of anti-atrophic effects of PGC-1s (42). 
Similar conclusions were derived from 
experiments in human aortic smooth muscle and 
endothelial cells where PGC-1 suppressed 
TNF-induced VCAM-1 and MCP-1 expression 
that contribute to inflammation in atherosclerosis 
(43). 
Mechanistically, PGC-1 and PGC-1 
lower phosphorylation of the NF-B family 
member p65 which limits its transcriptional 
activation potential. This is further substantiated 
by data from muscle-specific PGC-1 transgenic 
animals that also exhibit reduced p65 
phosphorylation (44). Diametrically opposed to 
this report, another recent publication states that 
p65 phosphorylation is higher in PGC-1 
transgenic muscle before as well as after 
injection of TNF (45). The exact role of PGC-
1 on muscle inflammation in vivo thus remains 
unresolved. In our cellular model, decreased p65 
phosphorylation unequivocally corresponds to 
the loss of IKK induction by TNF in PGC-1 
overexpressing cells and, interestingly, to 
diminished Akt activation. Akt-dependent 
phophorylation of p65 by IKK is an important 
mechanism to regulate p65 transactivation 
potential (36,46) and thus a good candidate to 
mediate the reduction observed (Fig. 8C). In 
addition to modulation of kinase activity, the 
involvement of a phosphatase is suggested by 
sustained phosphorylation of p65 after TNF 
treatment for 5 minutes even in the presence of 
PGC-1 and PGC-1. As okadaic acid treatment 
did not abrogate differences between conditions, 
PP2A and PP1 are however unlikely to account 
for this effect. Therefore, further experiments are 
needed to determine the contribution of different 
phosphatases in this setting.  
The transactivation potential of p65 is 
controlled by its phosphorylation status as it 
defines the affinity for cofactors important in 
suppressing or stimulating transcription of target 
genes (38). Decreased phosphorylation thus 
favors interaction with corepressors such as 
SMRT that decreases p65/p50 transactivation 
(47). Interestingly, SMRT levels are slightly 
induced by PGC-1 and accordingly could 
contribute to lower cytokine expression. 
Stabilization of corepressor complexes on DNA-
bound p65 is also fostered by nuclear receptor-
mediated transrepression (39). For example, 
PPAR is able to exert anti-inflammatory action 
by ligand-dependent and –independent 
transrepressive mechanisms (48,49). We found a 
marked induction of PPAR by PGC-1 and 
PGC-1, which presumably also contributes to 
negative regulation of pro-inflammatory 
cytokines by transrepression (Fig. 8C). This 
claim is substantiated by the reversal of the 
repressive PGC-1 effects on pro-inflammatory 
cytokine expression when PPAR was inhibited. 
PPAR regulates lipid metabolism and FFAs are 
able to serve as ligands for PPAR (50). Thus, 
the very pronounced suppressive effect of the 
PGC-1s on inflammatory gene expression 
observed after FFA treatment might reflect an 
additional ligand-dependent activation of 
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PPAR leading to an even stronger 
transrepression in that experimental context. 
Besides the reduction in p65 
phosphorylation that is exerted by both PGC-1 
and PGC-1, only the latter was further found to 
repress p65 and p50 transcription in the basal 
state and accordingly the ability of these proteins 
to bind to DNA response elements. This offers 
an attractive explanation for the very low 
cytokine levels observed in the presence of PGC-
1. The NF-B family members RelB and c-Rel 
were also suppressed transcriptionally in the 
basal state which puts PGC-1 in the position of 
a broader anti-inflammatory factor in skeletal 
muscle. Such anti-inflammatory potential was 
previously described only in macrophages, 
where PGC-1 is essential in alternative 
activation and ROS production (27,28). In 
contrast, PGC-1 does not alter expression of the 
classically activated / canonical NF-B isoforms 
p65 and p50. However, PGC-1 overexpression 
induces transcript and protein levels of the 
alternative isoforms p100/p52 and RelB. This 
indicates a switch towards noncanonical / 
alternative NF-B signaling. A recent 
publication outlined that alternative signaling via 
IKK and RelB induces an oxidative phenotype 
in muscle driven by PGC-1(51). Furthermore, 
activation of c-Rel and p50 was suggested to 
play a role in disuse atrophy (52). Finally, 
canonical p65 activation was linked to 
mitochondrial biogenesis in mouse embryonic 
fibroblasts and liver cells (53,54). All of these 
findings together with our data suggest a 
reciprocal, functional link between NF-B 
signaling and oxidative metabolism. A potential 
induction of the alternative NF-B pathway by 
PGC-1 in muscle therefore warrants further 
investigations. 
Strikingly, inflammatory gene 
transcription was often selectively regulated by 
the two PGC-1 coactivators depending on the 
stimulus and the specific gene. These findings 
argue against a general repressive effect of PGC-
1 and PGC-1 on tissue inflammation in 
muscle but rather indicate a specific, fine-tuned 
effect of these coactivators on NF-B target 
genes. For example, while TLR1/2-induced 
cytokine production was suppressed by both 
PGC-1 and PGC-1, only PGC-1 was able to 
block this production after treatment of the cells 
with a TLR4-specific ligand. Moreover, TLR6/2-
induced TNF expression was also diminished 
by PGC-1, which was however not the case for 
TLR6/2-induced expression of IL-6. This 
probably reflects the activation of pathways 
other than NF-B downstream of TLRs that are 
not subject to regulation by PGC-1 or targeted by 
only one of the PGC-1 isoforms, respectively. 
Interestingly, while neither PGC-1 nor PGC-1 
affected expression of TNF receptor 1 (TNFR1) 
(Suppl. Fig. 6A and 6B) both coactivators 
lowered mRNA levels of TLR1, TLR4 and 
TLR6 (Suppl. Fig. 6C and 6D). This 
downregulation might presumably contribute to 
the repressive effects observed with some TLR 
agonists. The expression pattern of TLR1, TLR4 
and TLR6 (Suppl. Fig. 6C and 6D) further 
resembles genes in cluster 2 of the microarray, 
confirming a broader influence of PGC-1s on 
inflammatory genes. Moreover, the selectivity of 
the PGC-1s most likely reflects the distinct 
expression pattern as well as the distinct 
functions of PGC-1 and PGC-1 in the 
regulation of skeletal muscle physiology that will 
have to be further dissected in future 
experiments. In any case however, the concept 
that PGC-1s selectively and specifically repress 
inflammatory processes and thereby avoid the 
harmful consequences of broad and general 
cytokine suppression is compelling. Once 
understood in greater detail, the therapeutic 
potential of targeting PGC-1s to modulate 
specific inflammatory responses in muscle would 
be immense. Obviously, patients suffering from 
obesity and type 2 diabetes would profit from 
lower systemic inflammation mediated by 
rectified gene expression of PGC-1 and PGC-
1 in skeletal muscle. Intriguingly however, 
muscle disorders like cachexia, muscular 
dystrophies, disuse atrophy or inflammatory 
myopathy also involve an inflammatory 
component with activation of the NF-B 
pathway (55-58). In fact, chronic stimulation of 
the classical NF-B pathway in muscle is 
sufficient to induce muscle wasting (5). 
Accordingly, mice heterozygous for p65 or 
harboring a genetic ablation of the IKK gene in 
the mdx background, a model for Duchenne 
muscular dystrophy, have improved pathology 
(59). Strikingly, ectopic elevation of PGC-1 in 
animal models for some of these diseases 
resulted in an amelioration of fiber damage and 
muscle functionality, e.g. in Duchenne muscular 
dystrophy, sarcopenia, a mitochondrial 
myopathy and denervation-induced fiber atrophy 
(20,21,44,60). Our data now suggest that at least 
part of the therapeutic effect of PGC-1 in these 
disease paradigms might stem from the anti-
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inflammatory effect. It is, thus, tempting to 
speculate that elevating PGC-1 and / or PGC-
1 in muscle would also be beneficial in other 
conditions of muscle wasting by limiting the 
detrimental inflammatory component of the 
disease. In fact, muscle adaptation to endurance 
training that correlate with increased PGC-1 
expression includes an increased resistance 
against fiber damage, tissue inflammation and, as 
a consequence, decreased exercise-induced 
muscle soreness. In contrast to PGC-1, the 
implications of the repressive effect of PGC-1 
on inflammatory gene expression remain less 
obvious until the physiological context of PGC-
1 regulation and the function of this coactivator 
in muscle tissue have been more clearly 
delineated. Nevertheless, by virtue of their 
ability to reduce NF-B activation, the PGC-1 
coactivators are promising targets to antagonize 
inflammatory reactions in skeletal muscle 
associated with a large number of diseases.  
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FIGURE LEGENDS 
 
FIGURE 1. PGC-1and PGC-1 suppress TNF-induced pro-inflammatory cytokines. A-D, 
Differentiated C2C12 myotubes overexpressing PGC-1 and GFP (Panels A and C) or PGC-1 and 
GFP (Panels B and D) were treated with TNF for 2h. Expression of pro-inflammatory cytokines was 
determined by real-time PCR (Panels A and B) and release of IL-6 into the medium quantified by 
ELISA (Panels C and D). Values represent the mean of at least 3 independent experiments +SEM. ## 
P≤0.01 GFP TNF versus GFP Ctrl, * P≤0.05, ** P≤0.01 PGC-1/ versus GFP. 
 
FIGURE 2. PGC-1and PGC-1 differentially suppress TLR agonist-induced pro-inflammatory 
cytokines. A, Differentiated C2C12 myotubes were tested for mRNA expression of TLR1-9. 
Expression values are arbitrarily normalized to those of TLR1. B, C2C12 cells were differentiated and 
treated with different TLR agonists for 2h. Expression of IL-6 and TNF was assessed by real-time 
PCR. C, C2C12 cells were transfected with an NFB reporter construct (or a mutated reporter 
construct as control) and treated with different TLR agonists for 2h. Luciferase activity was 
determined and is expressed as ratio of wt to mutated reporter gene values. D-G, Differentiated C2C12 
myotubes overexpressing PGC-1 and GFP (Panels D and E) or PGC-1 and GFP (Panels F and G) 
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were treated with agonists for TLR1/2, TLR4, TLR6/2 and TLR3 for 2h. Expression of pro-
inflammatory cytokines was determined by real-time PCR (Panels D and F) and release of IL-6 into 
the medium quantified by ELISA (Panels E and G). Values represent the mean of at least 3 
independent experiments +SEM. # P≤0.05, ## P≤0.01 TLR agonist treated versus Ctrl (A, B, D-G) or 
TLR expression versus TLR1 (C), * P≤0.05, ** P≤0.01 PGC-1/ versus GFP. 
 
FIGURE 3. PGC-1and PGC-1 differentially suppress fatty acid-induced pro-inflammatory 
cytokines. A, B, Differentiated C2C12 myotubes overexpressing PGC-1 and GFP (Panel A), or PGC-
1 and GFP (Panel B) were treated with different fatty acids (P=palmitic acid, O=oleic acid, 
M=myristic acid, S=stearic acid, L=linoleic acid, E=elaidic acid) for 16h. Expression of pro-
inflammatory cytokines was determined by real-time PCR. Values represent the mean of at least 3 
independent experiments +SEM. # P≤0.05, ## P≤0.01 GFP FFA versus GFP Ctrl, * P≤0.05, ** P≤0.01 
PGC-1/ versus GFP. 
 
FIGURE 4. Inflammatory pathways and NF-B activity are suppressed by PGC-1s. Differentiated 
C2C12 myotubes overexpressing PGC-1, PGC-1 and GFP were treated with TNF for 2h and 
subsequently subjected to a customized microarray analysis. A, Significantly regulated genes (P≤0.01) 
were clustered and are depicted as heat map. B, KEGG pathways enriched within each cluster 
(adjusted p-value≤0.05) are shown, the dotted line indicates an adjusted p-value of 0.01. 
(Abbreviations: cytok. = cytokine, pw = pathway, r. = receptor). C, Motifs overrepresented in the 
promoters of each cluster were identified and their z score distribution plotted. For a complete list see 
Suppl. Table 2A. D, Activity plot of NF-B (top scoring transcription factor motif) over different 
conditions as predicted by MARA (Motif Activity Response Analysis) and the corresponding 
sequence logo of the position weight matrix.  
 
FIGURE 5. PGC-1s suppress NF-B transcription activation potential without changing DNA 
binding or affecting NF-B expression levels. A, C2C12 cells were transfected with a wildtype and a 
mutated NFB reporter construct, p65 and increasing amounts of PGC-1 or PGC-1. Luciferase 
activity was determined after 24h and is expressed as ratio of wt reporter to mutated reporter gene 
expression. ## P< 0.01 PGC-1 versus Ctrl. B-E, Differentiated C2C12 myotubes overexpressing PGC-
1 and GFP (Panels B and D) or PGC-1 and GFP (Panels C and E) were treated with TNF for 2h. 
B, C, Expression of NF-B family members was determined by real-time PCR. D, E, DNA binding of 
NFB family members in nuclear extracts was measured by TransAM. Values represent the mean of 
at least 3 independent experiments +SEM. # P≤0.05, ## P≤0.01 GFP TNF versus GFP Ctrl, * P≤0.05, 
** P≤0.01 PGC-1/ versus GFP. 
 
FIGURE 6. PGC-1s diminish p65 phosphorylation at serine 536. Differentiated C2C12 myotubes 
overexpressing PGC-1, PGC-1 and GFP were treated with TNF for 2h. A, Protein abundance of 
NFB family members, pathway components, phospho-p65 (ser536), PGC-1, PGC-1 and -
Tubulin was assessed by immunoblotting. B, Quantification of phospho-p65 (ser536) and total p65 
protein levels, normalized to -Tubulin. Values represent the mean of at least 3 independent 
experiments +SEM. # P≤0.05, ## P≤0.01 GFP TNF versus GFP Ctrl, * P≤0.05, ** P≤0.01 PGC-1/ 
versus GFP. 
 
FIGURE 7. Dephosphorylation of p65 is a potential molecular mechanism for diminished cytokine 
expression. A, Differentiated C2C12 myotubes overexpressing PGC-1, PGC-1 and GFP were 
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treated with TNF for 2h. Protein levels of Akt and phospho-Akt (ser473) were determined by 
immunoblotting. B, Differentiated C2C12 myotubes overexpressing PGC-1, PGC-1 and GFP were 
treated with TNF for 5 minutes and 2h, respectively. Protein abundance of Phospho-p65 (ser536) and 
total p65 was assessed by immunoblotting. C, Quantification of Phospho-p65 (ser536) levels from B, 
normalized to -Tubulin. D, Differentiated C2C12 myotubes overexpressing PGC-1, PGC-1 and 
GFP were treated with TNF for 2h in the presence or absence of okadaic acid (OA). Protein 
abundance of phospho-p65 (ser536), total p65, PGC-1 and PGC-1 was assessed by immunoblotting 
E, F, Quantification of PGC-1 and PGC-1 protein levels from D, normalized to -Tubulin (Panel 
E). Quantification of Phospho-p65 (ser536) protein levels from D, normalized to -Tubulin (Panel F). 
Values represent the mean of at least 3 independent experiments +SEM. # P≤0.05, ## P≤0.01 GFP OA 
versus GFP Ctrl, * P≤0.05, ** P≤0.01 PGC-1/ versus GFP. 
 
FIGURE 8. Transrepression of p65 is a potential molecular mechanism for diminished cytokine 
expression. A, B, Differentiated C2C12 myotubes overexpressing PGC-1 and GFP (Panel A) or 
PGC-1 and GFP (Panel B) were treated with TNF for 2h. Expression of coactivator and corepressor 
proteins, and of nuclear receptor PPAR was determined by real-time PCR. * P≤0.05, ** P≤0.01 
PGC-1/ versus GFP. C, Proposed model of PGC-1/ interference with NFB signaling. Gene-, 
activator- and PGC-1-specific repression of NFB target genes is mediated by reduced 
phosphorylation of p65, transcriptional induction of PPAR and subsequent transrepression as well as 
activation of an unknown protein phosphatase by both PGC-1s. Furthermore, PGC-1 specifically 
inhibits p65 and p50 expression while PGC-1 elevates members of the NFB family involved in the 
alternative, non-canonical activation (not depicted). 
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